1. Trang chủ
  2. » Kỹ Thuật - Công Nghệ

Biochemistry, 4th Edition P79 pdf

10 169 0
Tài liệu đã được kiểm tra trùng lặp

Đang tải... (xem toàn văn)

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 10
Dung lượng 468,7 KB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

Eicosanoids Are Local Hormones Animal cells can modify arachidonic acid and other polyunsaturated fatty acids, in processes often involving cyclization and oxygenation, to produce so-cal

Trang 1

2% to 8% of the lipids in most animal membranes, but breakdown products of PI,

in-cluding inositol-1,4,5-trisphosphate and diacylglycerol, are second messengers in a

vast array of cellular signaling processes

Dihydroxyacetone Phosphate Is a Precursor to the Plasmalogens

Certain glycerophospholipids possess alkyl or alkenyl ether groups at the 1-position

in place of an acyl ester group These glyceroether phospholipids are synthesized

from dihydroxyacetone phosphate (Figure 24.23) Acylation of dihydroxyacetone

phosphate (DHAP) is followed by an exchange reaction, in which the acyl group is

removed as a carboxylic acid and a long-chain alcohol adds to the 1-position This

C

O

CH2

H C

OH O

CH2 O

O

P O–

O–

CoA S

O

C R

C

CH2

O

O

CH2 O

O

P O–

O–

O

C

R

HO CH2CH2R1

R C O–

C

CH2 O

O

CH2 O P O–

O–

R1CH2CH2

R1CH2CH2

R1CH2CH2

O

+

HOCH

CH2 O

CH2 O P O–

O–

O C

R2

O C

CH2 O

CH2 O P O–

O–

R1CH2CH2 O

O H CDP- ethanolamine

O C

CH2

CH2 O P O

O–

O H

CH2CH2NH3 +

+ +

2 H2O

+

O

C

CH2 O

CH2 O P O

O–

O H

CH2CH2NH3 +

H C

R1

CDP

NAD+

NADH

NADP+

NADPH H +

H +

O2

CoASH

CoASH

1

2

3

4

5 6

Dihydroxyacetone phosphate

1-Acyldihydroxyacetone phosphate

1-Acyldihydroxyacetone

phosphate synthase

Dihydroxyacetone

phosphate

acyltransferase

1-Alkyldihydroxyacetone phosphate

1-Alkyldihydroxyacetone

phosphate

oxidoreductase

1-Alkylglycero-3-phosphate

1-Alkylglycerophosphate acyltransferase

1-Alkyl-2-acylglycero-3-phosphate

CDP-ethanolamine transferase 1-Alkyl-2-acylglycero-3-phosphoethanolamine

1-Alkyl-2-acylglycero-phosphoethanolamine desaturase

Plasmalogen

FIGURE 24.23 Biosynthesis of plasmalogens in animals (1) Acylation at C-1 is followed by (2) exchange of the acyl group for a long-chain alcohol (3) Reduction of the keto group at C-2 is followed by (4 and 5) transferase

reactions, which add an acyl group at C-2 and a polar head-group moiety (as shown here for

phospho-ethanolamine), and a (6) desaturase reaction that forms a double bond in the alkyl chain The first two

enzymes are of cytoplasmic origin, and the last transferase is located at the endoplasmic reticulum.

Trang 2

744 Chapter 24 Lipid Biosynthesis

long-chain alcohol is derived from the corresponding CoA by means of an

acyl-CoA reductase reaction involving oxidation of two molecules of NADH The 2-keto

group of the DHAP backbone is then reduced to an alcohol, followed by acylation The resulting 1-alkyl-2-acylglycero-3-phosphate can react in a manner similar to phosphatidic acid to produce ether analogs of phosphatidylcholine,

phosphatidyl-ethanolamine, and so forth (Figure 24.23) In addition, specific desaturase enzymes

associated with the ER can desaturate the alkyl ether chains of these lipids as shown The products, which contain ,-unsaturated ether-linked chains at the C-1

posi-tion, are plasmalogens; they are abundant in cardiac tissue and in the central

nervous system The desaturases catalyzing these reactions are distinct from but sim-ilar to those that introduce unsaturations in fatty acyl-CoAs

Platelet-Activating Factor Is Formed by Acetylation

of 1-Alkyl-2-Lysophosphatidylcholine

A particularly interesting ether phospholipid with unusual physiological

prop-erties, 1-alkyl-2-acetylglycerophosphocholine, also known as platelet-activating

factor, possesses an alkyl ether at C-1 and an acetyl group at C-2 (Figure 24.24) The very short chain at C-2 makes this molecule much more water soluble than typical glycerolipids Platelet-activating factor displays a dramatic ability to dilate blood vessels (and thus reduce blood pressure in hypertensive animals) and to aggregate platelets

Sphingolipid Biosynthesis Begins with Condensation of Serine and Palmitoyl-CoA

Sphingolipids, ubiquitous components of eukaryotic cell membranes, are present at high levels in neural tissues The myelin sheath that insulates nerve axons is particu-larly rich in sphingomyelin and other related lipids Prokaryotic organisms normally

do not contain sphingolipids Sphingolipids are built upon sphingosine backbones rather than glycerol The initial reaction, which involves condensation of serine and

palmitoyl-CoA with release of bicarbonate, is catalyzed by 3-ketosphinganine synthase,

HO C

CH2 O

CH2 O

O

P O O–

RCH2CH2

H

CH2CH2N(CH+ 3)3

O

CH3C SCoA

O

CH3C O–

O C

CH2 O

CH2 O

O

P O O–

RCH2CH2

H

CH2CH2N(CH+ 3)3 O

CH3C

1-Alkyl-2-lysophosphatidylcholine

Acetyl-CoA: 1-alkyl-2-lysoglycero-phosphocholine transferase Acetylhydrolase

1-Alkyl-2-acetylglycerophosphocholine (platelet-activating factor, PAF)

CoASH

H2O

FIGURE 24.24 Platelet-activating factor, formed from

1-alkyl-2-lysophosphatidylcholine by acetylation at C-2,

is degraded by the action of acetylhydrolase.

Trang 3

a PLP-dependent enzyme (Figure 24.25) Reduction of the ketone product to form

sphinganine is catalyzed by 3-keto-sphinganine reductase, with NADPH as a reactant.

In the next step, sphinganine is acylated to form N-acyl sphinganine, which is then

desaturated to form ceramide Sphingosine itself does not appear to be an

interme-diate in this pathway in mammals

CH3(CH2)14

O

C S CoA

–OOC C CH2OH +NH3 H

CH3(CH2)14

O

C C CH2OH +NH3 H

CH3(CH2)14 C C CH2OH

+NH3

H

H

CH3(CH2)12

CH3 (CH2)n

OH

OH

O

NH H

C H

H

C

C H

3-Ketosphinganine

synthase

2S-3-Ketosphinganine

N-acyl-sphinganine

Ceramide

X

XH2

2S,3R-Sphinganine

+

3-Ketosphinganine reductase

HCO3–

NADP+

NADPH H+

CoASH

H2O

SCoA

CoASH

FIGURE 24.25 Biosynthesis of sphingolipids in animals begins with the 3-ketosphinganine synthase reaction, a PLP-dependent condensation of palmitoyl-CoA and serine Subsequent reduction of the keto group, acyla-tion, and desaturation (via reduction of an electron acceptor, X) form ceramide, the precursor of other sphingolipids.

Trang 4

746 Chapter 24 Lipid Biosynthesis

Ceramide Is the Precursor for Other Sphingolipids and Cerebrosides Ceramide is the building block for all other sphingolipids Sphingomyelin, for

example, is produced by transfer of phosphocholine from phosphatidylcholine

(Figure 24.26) Glycosylation of ceramide by sugar nucleotides yields cerebrosides,

such as galactosylceramide, which makes up about 15% of the lipids of myelin sheath

CH2OH

O O HO

OH

OH

H N O C

H C C H (CH2)12

CH2 CH

CHOH

R1

UDP-Gal

UDP

CH2OH

O H

H

H

OH H

OH

O

N H O

HC

C OH

C

CH2

R2

O

CH2OH O HO

H

H H OH

H

OH H

CH2OH O H

H

H H OH

H

OH

O

N H O

HC

C OH

C

CH2

R2

O

CH2OH O

H

H H OH

H

OH H

CMP- sialic acid

O

CH2OH O H H OH

H H

C O

CH3 HO

O H

H

H H OH

H

OH

O

N H O

HC

C OH

C

CH2

R2

O

CH2OH O

H

H H O

H

OH H

O

CH2OH O H H OH

H H

C O

CH3 HO

O

H H

COH H H HN

OH H

COO–

C O

CH3

H HCOH

CH2OH

CH2OH

UDP- Glu

UDP UDP- Gal UDP

CH3

H N O C

H C C H (CH2)12

CH2

CH2OH CH

CHOH

R1

H N O

O

O

O P

– O

C

H C C H (CH2)12

CH2

CH2

CH3

CH3

+

H3C

C

CHOH

R1

1,2-Diacylglycerol

Phosphatidyl-choline

-D -Galactosylceramide

UDP- galacto-syltransferase

-D -Galactosyl-(1 4)--D -glucosylceramide

UDP- N-Acetylgalactosamine

UDP

N-Acetylgalactosaminyltransferase

-D-N-Acetylgalactosamine-(1

4)--D -galactosyl-(1 4)--D -glucosylceramide

CMP

Sialytransferase

Ganglioside GM

Ceramide

Sphingomyelin

FIGURE 24.26 Glycosylceramides (such as

galactosyl-ceramide), gangliosides, and sphingomyelins are

synthe-sized from ceramide in animals.

Trang 5

structures Cerebrosides that contain one or more sialic acid (N-acetylneuraminic

acid) moieties are called gangliosides Several dozen gangliosides have been

charac-terized, and the general form of the biosynthetic pathway is illustrated for the

case of ganglioside GM2 (Figure 24.26) Sugar units are added to the developing

ganglioside from nucleotide derivatives, including UDP–N-acetylglucosamine,

UDP–galactose, and UDP–glucose

Are Their Functions?

Eicosanoids,so named because they are all derived from 20-carbon fatty acids,

are ubiquitous breakdown products of phospholipids In response to appropriate

stimuli, cells activate the breakdown of selected phospholipids (Figure 24.27)

Phospholipase A2(see Chapter 8) selectively cleaves fatty acids from the C-2

po-sition of phospholipids Often these are unsaturated fatty acids, among which is

arachidonic acid Arachidonic acid may also be released from phospholipids by

the combined actions of phospholipase C (which yields diacylglycerols) and

dia-cylglycerol lipase (which releases fatty acids)

Eicosanoids Are Local Hormones

Animal cells can modify arachidonic acid and other polyunsaturated fatty acids, in

processes often involving cyclization and oxygenation, to produce so-called local

hor-mones that (1) exert their effects at very low concentrations and (2) usually act near

their sites of synthesis These substances include the prostaglandins (PG) (Figure

24.27) as well as thromboxanes (Tx), leukotrienes, and other hydroxyeicosanoic acids.

Thromboxanes, discovered in blood platelets (thrombocytes), are cyclic ethers (TxB2is

actually a hemiacetal; see Figure 24.27) with a hydroxyl group at C-15

Prostaglandins Are Formed from Arachidonate by Oxidation

and Cyclization

All prostaglandins are cyclopentanoic acids derived from arachidonic acid The

biosynthesis of prostaglandins is initiated by an enzyme associated with the ER, called

prostaglandin endoperoxide H synthase (PGHS), also known as cyclooxygenase

(COX).The enzyme catalyzes simultaneous oxidation and cyclization of arachidonic

acid The enzyme is viewed as having two distinct activities, COX and peroxidase

(POX), as shown in Figure 24.28

A DEEPER LOOK

The Discovery of Prostaglandins

The name prostaglandin was given to this class of compounds by Ulf

von Euler, their discoverer, in Sweden in the 1930s He extracted

fluids containing these components from human semen Because

he thought they originated in the prostate gland, he named them

prostaglandins Actually, they were synthesized in the seminal

vesi-cles, and it is now known that similar substances are synthesized in

most animal tissues (both male and female) Von Euler observed

that injection of these substances into animals caused smooth

mus-cle contraction and dramatic lowering of blood pressure

Von Euler (and others) soon found that it is difficult to analyze

and characterize these obviously interesting compounds because

they are present at extremely low levels Prostaglandin E2, or

PGE2, is present in human serum at a level of less than 1014M!

In addition, they often have half-lives of only 30 seconds to a few

minutes, not lasting long enough to be easily identified Moreover, most animal tissues upon dissection and homogenization rapidly synthesize and degrade a variety of these substances, so the amounts obtained in isolation procedures are extremely sensitive

to the methods used and highly variable even when procedures are carefully controlled Sune Bergström, Bengt Samuelsson, and their colleagues described the first structural determinations of prostaglandins in the late 1950s In the early 1960s, dramatic ad-vances in laboratory techniques, such as NMR spectroscopy and mass spectrometry, made further characterization possible Von Euler received the Nobel Prize for Physiology or Medicine in 1970, and Bergström, Samuelsson, and John Vane shared the Nobel for Physiology or Medicine in 1982

Trang 6

748 Chapter 24 Lipid Biosynthesis

A Variety of Stimuli Trigger Arachidonate Release and Eicosanoid Synthesis

The release of arachidonate and the synthesis or interconversion of eicosanoids can

be initiated by a variety of stimuli, including histamine, hormones such as epineph-rine and bradykinin, proteases such as thrombin, and even serum albumin An im-portant mechanism of arachidonate release and eicosanoid synthesis involves tissue injury and inflammation When tissue damage or injury occurs, special inflammatory

OH

O

COO–

HO

OH

OH

COO–

HO

–OOC

O

COO–

O

OH HO

H

COO–

OH

O

O

COO–

OH

HO

O

HO H

COO–

H S CH2

CH C O

N H

CH2COO–

NH C O

CH2CH2 CH

COO–

H3+N

2 O2

PGE 2

PGF 2a

PGI 2

TxB 2

PGH 2

PGD 2

Leukotriene C

Arachidonate

Activation of PLC and diacylglycerol lipase

Activation of PLA2

Receptor

Hormone (or other stimulus)

Phospholipids

FIGURE 24.27 Arachidonic acid, derived from breakdown of phospholipids (PL), is the precursor of prostaglandins, thromboxanes, and leukotrienes The letters used to name the prostaglandins are assigned on the basis of similar-ities in structure and physical properties The class denoted PGE, for example, consists of -hydroxyketones that

are soluble in ether, whereas PGF denotes 1,3-diols that are soluble in phosphate buffer PGA denotes prosta-glandins possessing ,-unsaturated ketones.The number following the letters refers to the number of carbon–

carbon double bonds Thus, PGE 2 contains two double bonds.

Trang 7

cells, monocytes and neutrophils, invade the injured tissue and interact with the

resi-dent cells (such as smooth muscle cells and fibroblasts) This interaction typically leads

to arachidonate release and eicosanoid synthesis Examples of tissue injury in which

eicosanoid synthesis has been characterized include heart attack (myocardial

infarc-tion), rheumatoid arthritis, and ulcerative colitis

“Take Two Aspirin and…” Inhibit Your Prostaglandin Synthesis

In 1971, biochemist John Vane was the first to show that aspirin (acetylsalicylate;

Fig-ure 24.29) exerts most of its effects by inhibiting the biosynthesis of prostaglandins

Its site of action is PGHS COX activity is destroyed when aspirin O -acetylates Ser530

COOH COX

POX

COOH

.

O

COOH

O OH H

H H

H

COOH

H H H

H

O

O

O

O

H

O

O O

5, 8,11,14-Eicosatetraenoic acid (arachidonic acid)

Peroxide radical

PGG 2

PGH 2

O O

FIGURE 24.28 Prostaglandin endoperoxide H synthase (PGHS), the enzyme that converts arachidonic acid to prostaglandin PGH 2 , possesses two distinct activities: cyclooxygenase (COX) and a glutathione-dependent hydroperoxidase (POX) The mechanism of the reaction begins with hydrogen atom abstraction by a tyrosine radical on the enzyme, followed by rearrangement to cyclize and incorporate two oxygen molecules Reduc-tion of the peroxide at C15 completes the reacReduc-tion COX

is the site of action of aspirin and other analgesic agents.

O C CH3

O Ser

COO–

O

C CH3

CH CH

CH3

CH2

CH3

O O

COO–

OH Ser

H3C

H3C

(b) (a)

Salicylate

Active cyclooxygenase Acetaminophen

Ibuprofen

Inactive cyclooxygenase Acetylsalicylate (aspirin)

FIGURE 24.29 (a) The structures of several common analgesic agents Acetaminophen is marketed under the trade

name Tylenol Ibuprofen is sold as Motrin, Nuprin, and Advil (b) Acetylsalicylate (aspirin) inhibits the COX activity of

endoperoxide synthase via acetylation (covalent modification) of Ser 530

Trang 8

750 Chapter 24 Lipid Biosynthesis

on the enzyme From this you may begin to infer something about how prosta-glandins (and aspirin) function Prostaprosta-glandins are known to enhance inflammation

in animal tissues Aspirin exerts its powerful anti-inflammatory effect by inhibiting this first step in their synthesis Aspirin does not have any measurable effect on the peroxidase activity of the synthase Other nonsteroidal anti-inflammatory agents,

such as ibuprofen (Figure 24.29) and phenylbutazone, inhibit COX by competing at

the active site with arachidonate or with the peroxyacid intermediate (PGG2, as in Figure 24.28) See A Deeper Look above

The most prevalent steroid in animal cells is cholesterol (Figure 24.30) Plants

con-tain no cholesterol, but they do concon-tain other steroids very similar to cholesterol in

structure (see page 236) Cholesterol serves as a crucial component of cell mem-branes and as a precursor to bile acids (such as cholate, glycocholate, taurocholate) and steroid hormones (such as testosterone, estradiol, progesterone) Also, vitamin

D3is derived from 7-dehydrocholesterol, the immediate precursor of cholesterol Liver

is the primary site of cholesterol biosynthesis

A DEEPER LOOK

The Molecular Basis for the Action of Nonsteroidal Anti-inflammatory Drugs

Prostaglandins are potent mediators of inflammation The first and

committed step in the production of prostaglandins from

arachi-donic acid is the bis-oxygenation of arachidonate to prostaglandin

PGG2 This is followed by reduction to PGH2in a peroxidase

reac-tion Both these reactions are catalyzed by PGHS or COX This

en-zyme is inhibited by the family of drugs known as nonsteroidal

anti-inflammatory drugs, or NSAIDs Aspirin, ibuprofen, flurbiprofen,

and acetaminophen (trade name Tylenol) are all NSAIDs

There are two isoforms of COX in animals: COX-1, which car-ries out normal, physiological production of prostaglandins, and COX-2, which is induced by cytokines, mitogens, and endotoxins

in inflammatory cells and is responsible for the production of prostaglandins in inflammation

The enzyme structure shown in panel a is that of residues 33 to

583 of COX-1 from sheep, inactivated by ibuprofen (cyan) These

551 residues comprise three distinct domains The first of these,

(a)pdb id  1EQG (b) Superposition of pdb id  1EQG and 1CX2

Trang 9

Mevalonate Is Synthesized from Acetyl-CoA Via HMG-CoA Synthase

The cholesterol biosynthetic pathway begins in the cytosol with the synthesis of

mevalonate from acetyl-CoA (Figure 24.31) The first step is the ␤-ketothiolase–

catalyzed Claisen condensation of two molecules of acetyl-CoA to form

acetoacetylCoA In the next reaction, acetylCoA and acetoacetylCoA join to form 3hydroxy

-3-methylglutaryl -CoA, which is abbreviated HMG -CoA The reaction, a second Claisen

condensation, is catalyzed by HMG-CoA synthase The third step in the pathway is

residues 33 to 72, is a small, compact module that is similar to

epi-dermal growth factor The second domain, composed of residues

73 to 116, forms a right-handed spiral of four -helical segments.

These-helical segments form a membrane-binding motif The

helical segments are amphipathic, with most of the hydrophobic

residues facing away from the protein, where they can interact

with a lipid bilayer The third domain of the COX enzyme, the

cat-alytic domain, is a globular structure that contains both the COX

and the peroxidase active sites

The COX active site lies at the end of a long, narrow,

hydro-phobic tunnel or channel Three of the -helices of the

membrane-binding domain lie at the entrance to this tunnel The walls of

the tunnel are defined by four -helices, formed by residues

106 to 123, 325 to 353, 379 to 384, and 520 to 535

The COX-1 structure shown in panel a has a molecule of

ibupro-fen bound in the tunnel Deep in the tunnel, at the far end, lies

Tyr385, a catalytically important residue Heme-dependent

peroxi-dase activity is implicated in the formation of a proposed Tyr385

rad-ical, which is required for COX activity Aspirin and other NSAIDs

block the synthesis of prostaglandins by filling and blocking the

tun-nel, preventing the migration of arachidonic acid to Tyr385in the ac-tive site at the back of the tunnel

Why do the new “COX-2 inhibitors” bind to (and inhibit) COX-2 but not COX-1? A single amino acid substitution makes all the dif-ference Panel b shows an overlay of COX-1 (1EQG) and COX-2 (1CX2) structures COX-2 has a valine (blue) at position 523, which leaves room for binding of a Celebrex-like inhibitor (orange) On the other hand, COX-1 has bulkier isoleucine (red) at position 523, which prevents binding of the inhibitor

COX-2 inhibitors were introduced as pain medications in 1997, and by 2004 nearly half of the 100 million prescriptions written an-nually for NSAIDs in the United States were COX-2 inhibitors However, several COX-2 inhibitors were taken off the U.S market

in late 2004 and early 2005, when their use was linked to heart at-tacks and strokes in a small percentage of users Since that time, prescriptions for COX-2 inhibitors have dropped by 65% Inter-estingly, although COX-2 inhibitors were originally intended to al-leviate pain without the risk of adverse gastrointestinal effects, less than 5% of patients that used COX-2 prescriptions at the peak of their popularity were at high risk for these adverse effects

COOH COOH

O

O

CH2Br CH3

CH3

H3N

CHF2

NH2

CF3 O

O

O

S O O

N N

N N

Ibuprofen

* Abby Garrett took this.

(c)

H

HO

1

2

3

4 5

CH19 3

10 9 8

6 7

11 13

14

12 16 17 15

H3C

18

C

H3C21

20

CH3

H

25

26

27

2 1

8 9 10

11

13

16 17

CH3

18

H C

H3C21

20

CH3

H

25

26

27

CH3

19

12

FIGURE 24.30 The structure of cholesterol, drawn (a) in the traditional planar motif and (b) in a form that more

accurately describes the conformation of the ring system.

Trang 10

752 Chapter 24 Lipid Biosynthesis

the rate-limiting step in cholesterol biosynthesis Here, HMG-CoA undergoes two

NADPH-dependent reductions to produce 3R -mevalonate (Figure 24.32) The

reac-tion is catalyzed by HMG-CoA reductase, a 97-kD glycoprotein that spans the ER

membrane with its active site facing the cytosol As the rate-limiting step, HMG-CoA reductase is the principal site of regulation in cholesterol synthesis

Three different regulatory mechanisms are involved:

1 Phosphorylation by cAMP-dependent protein kinases inactivates the reductase This inactivation can be reversed by two specific phosphatases (Figure 24.33)

2 Degradation of HMG-CoA reductase This enzyme has a half-life of only

3 hours, and the half-life itself depends on cholesterol levels: High [cholesterol] means a short half-life for HMG-CoA reductase

3 Gene expression Cholesterol levels control the amount of mRNA If terol] is high, levels of mRNA coding for the reductase are reduced If [choles-terol] is low, more mRNA is made (Regulation of gene expression is discussed

in Chapter 29.)

A Thiolase Brainteaser Asks Why Thiolase Can’t Be Used

in Fatty Acid Synthesis

If acetate units can be condensed by the thiolase reaction to yield acetoacetate in the first step of cholesterol synthesis, why couldn’t this same reaction also be used in fatty acid synthesis, avoiding all the complexity of the fatty acyl synthase? The answer is

O

–OOC

CH3 C SCoA

O

CH3 C SCoA

O

CH3 C

O

CH2 C SCoA

O

CH2 C SCoA

CH3 C OH

CH2

CH3 C OH

CH2

H H

2 H+

2

O

CH3 C SCoA

Acetyl-CoA

OH

NADP+

NADPH

CoASH

CoASH

CoASH

Acetyl-CoA

Acetyl-CoA

Acetoacetyl-CoA

3-Hydroxy-3-methylglutaryl-CoA

(HMG-CoA)

HMG-CoA reductase

3R -Mevalonate

Thiolase

HMG-CoA synthase

FIGURE 24.31 The biosynthesis of 3R-mevalonate from

acetyl-CoA.

–OOC

O

CH2 C S

CH3 C OH

CH2

(a)

3-Hydroxy-3- methylglutaryl-CoA (HMG-methylglutaryl-CoA)

CH3 C

OH

CH2

H H

3R -Mevalonate

H H

H+

N

C

NH2

R First

Second

–OOC

O

CH2 C S

CH3 C

OH

CH2

Enzyme-bound intermediate

H H

N

C

NH2

R O H

O

H

OH NADPH NADPH

CoASH

CoA

CoA

(b)

HMG-CoA Reductase (pdb id = 1DQA)

ANIMATED FIGURE 24.32 (a) A reaction mechanism for HMG-CoA

reductase Two successive NADPH-dependent reductions convert the thioester, HMG-CoA,

to a primary alcohol (b) HMG-CoA reductase structure See this figure animated at

www.cengage.com/login.

Ngày đăng: 06/07/2014, 14:20

TỪ KHÓA LIÊN QUAN

TÀI LIỆU CÙNG NGƯỜI DÙNG

TÀI LIỆU LIÊN QUAN